Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fibrogen Inc CS 350 Bay Street Suite 100 #6009 SAN FRANCISCO CA 94158 USA

www.fibrogen.com Employees: 225 P: 415-978-1200

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 39,281
Enterprise Value, $K 83,371
Shares Outstanding, K 4,045
Float, K 3,921
% Float 96.93%
Short Interest, K 113
Short Float 0.00%
Days to Cover 3.65
Short Volume Ratio 0.38
% of Insider Shareholders 3.07%
% of Institutional Shareholders 72.71%

Financials:

Annual Sales, $ 29,620 K
Annual Net Income, $ -47,580 K
Last Quarter Sales, $ 1,080 K
Last Quarter Net Income, $ 200,640 K
EBIT, $ -124,040 K
EBITDA, $ -123,030 K

Growth:

1-Year Return -37.80%
3-Year Return -98.11%
5-Year Return -99.10%
5-Year Revenue Growth -88.46%
5-Year Earnings Growth -71.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.61 on 11/10/25
Next Earnings Date 03/16/26
Earnings Per Share ttm -10.99
EPS Growth vs. Prev Qtr 52.37%
EPS Growth vs. Prev Year 62.12%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 06/17/25

FGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -26.27%
Profit Margin % -160.63%
Debt/Equity 0.00
Price/Sales 4.73
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.99
Interest Coverage -17.59
60-Month Beta 0.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar